Results of a phase 3 study presented at the International Diabetes Federation 2011 World Diabetes Congress in Dubai, United Arab Emirates, demonstrate that when added to sulfonylurea therapy, dapagliflozin reduced HbA1c at 24 weeks vs. placebo plus sulfonylurea in patients with type 2 diabetes. The reduction was maintained at 48 weeks, according to a press release. Patients assigned to dapagliflozin...
Search This Blog
-----------------------------------------------------------------------------------------------------------------------------------------------------------------
Showing posts with label medical studies.. Show all posts
Showing posts with label medical studies.. Show all posts